Salarius Pharmaceuticals (SLRX) Competitors $4.22 +0.29 (+7.48%) As of 01:27 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock SLRX vs. HCWB, PRTG, BMRA, OBSV, PALI, NBY, BCDA, TNFA, EVOK, and ENTOShould you be buying Salarius Pharmaceuticals stock or one of its competitors? The main competitors of Salarius Pharmaceuticals include HCW Biologics (HCWB), Portage Biotech (PRTG), Biomerica (BMRA), ObsEva (OBSV), Palisade Bio (PALI), NovaBay Pharmaceuticals (NBY), BioCardia (BCDA), TNF Pharmaceuticals (TNFA), Evoke Pharma (EVOK), and Entero Therapeutics (ENTO). These companies are all part of the "pharmaceutical products" industry. Salarius Pharmaceuticals vs. Its Competitors HCW Biologics Portage Biotech Biomerica ObsEva Palisade Bio NovaBay Pharmaceuticals BioCardia TNF Pharmaceuticals Evoke Pharma Entero Therapeutics Salarius Pharmaceuticals (NASDAQ:SLRX) and HCW Biologics (NASDAQ:HCWB) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends. Which has more risk & volatility, SLRX or HCWB? Salarius Pharmaceuticals has a beta of 0.44, suggesting that its stock price is 56% less volatile than the S&P 500. Comparatively, HCW Biologics has a beta of 0.62, suggesting that its stock price is 38% less volatile than the S&P 500. Does the media refer more to SLRX or HCWB? In the previous week, Salarius Pharmaceuticals' average media sentiment score of 1.00 beat HCW Biologics' score of 1.00 indicating that Salarius Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Salarius Pharmaceuticals Positive HCW Biologics Positive Do analysts recommend SLRX or HCWB? HCW Biologics has a consensus target price of $35.00, suggesting a potential upside of 772.82%. Given HCW Biologics' stronger consensus rating and higher probable upside, analysts clearly believe HCW Biologics is more favorable than Salarius Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Salarius Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00HCW Biologics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Do institutionals & insiders believe in SLRX or HCWB? 11.9% of Salarius Pharmaceuticals shares are held by institutional investors. Comparatively, 3.0% of HCW Biologics shares are held by institutional investors. 1.2% of Salarius Pharmaceuticals shares are held by company insiders. Comparatively, 42.7% of HCW Biologics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Is SLRX or HCWB more profitable? Salarius Pharmaceuticals has a net margin of 0.00% compared to HCW Biologics' net margin of -1,368.55%. HCW Biologics' return on equity of 0.00% beat Salarius Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Salarius PharmaceuticalsN/A -556.47% -192.35% HCW Biologics -1,368.55%N/A -40.72% Which has stronger valuation and earnings, SLRX or HCWB? Salarius Pharmaceuticals has higher earnings, but lower revenue than HCW Biologics. HCW Biologics is trading at a lower price-to-earnings ratio than Salarius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSalarius PharmaceuticalsN/AN/A-$5.58M-$43.48-0.10HCW Biologics$2.57M3.35-$30.02M-$14.04-0.29 SummaryHCW Biologics beats Salarius Pharmaceuticals on 9 of the 14 factors compared between the two stocks. Get Salarius Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SLRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SLRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SLRX vs. The Competition Export to ExcelMetricSalarius PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.15M$2.68B$6.12B$10.53BDividend YieldN/A53.56%5.51%4.67%P/E Ratio-0.1023.9785.7226.88Price / SalesN/A602.00581.25184.02Price / CashN/A28.3526.3031.10Price / Book0.305.5113.226.67Net Income-$5.58M$32.78M$3.30B$276.44M7 Day Performance15.10%3.93%4.78%3.10%1 Month Performance-10.32%9.51%8.42%10.19%1 Year Performance-80.84%-2.23%87.67%40.32% Salarius Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SLRXSalarius Pharmaceuticals0.6988 of 5 stars$4.22+7.5%N/A-81.4%$2.15MN/A-0.1020Positive NewsHigh Trading VolumeHCWBHCW Biologics1.8177 of 5 stars$3.77-1.8%$35.00+828.4%-77.6%$8.03M$832.84K-0.2740Positive NewsGap DownPRTGPortage BiotechN/A$7.63+9.6%N/A+38.5%$8.01MN/A-0.186Gap UpHigh Trading VolumeBMRABiomerica0.1107 of 5 stars$2.82-1.2%N/A+12.7%$7.94M$5.31M-1.2160News CoverageNegative NewsShort Interest ↑OBSVObsEvaN/AN/AN/AN/A$7.94MN/A0.0050PALIPalisade Bio2.298 of 5 stars$0.87-6.2%$12.00+1,287.3%-44.5%$7.89M$250K-0.2110Short Interest ↑Gap UpNBYNovaBay PharmaceuticalsN/A$1.31-16.0%$0.85-35.1%N/A$7.87M$9.78M-0.0230Positive NewsGap DownBCDABioCardia3.8009 of 5 stars$1.31-6.8%$25.00+1,815.7%-48.9%$7.67M$60K-0.7140Positive NewsShort Interest ↓TNFATNF Pharmaceuticals0.1487 of 5 stars$4.08-12.1%N/A-96.3%$7.54MN/A-0.026Negative NewsGap DownEVOKEvoke Pharma0.8629 of 5 stars$4.83+0.2%N/A-10.9%$7.54M$10.25M-1.894Positive NewsShort Interest ↓ENTOEntero TherapeuticsN/A$4.72-4.8%N/A+134.0%$7.53MN/A0.009News CoverageGap Down Related Companies and Tools Related Companies HCWB Competitors PRTG Competitors BMRA Competitors OBSV Competitors PALI Competitors NBY Competitors BCDA Competitors TNFA Competitors EVOK Competitors ENTO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SLRX) was last updated on 10/7/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Salarius Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Salarius Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
